A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer

Men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer (NEPC/AVPC) have a poor prognosis and limited treatment options, and immunotherapy has not been tested in such patients. We conducted an open label single center phase 2 trial (NCT03179410) of men with progressive N...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Prostate cancer and prostatic diseases Ročník 25; číslo 4; s. 762 - 769
Hlavní autoři:	Brown, Landon C, Halabi, Susan, Somarelli, Jason A, Humeniuk, Michael, Wu, Yuan, Oyekunle, Taofik, Howard, Lauren, Huang, Jiaoti, Anand, Monika, Davies, Catrin, Patel, Prekshaben, Staats, Janet, Weinhold, Kent J, Harrison, Michael R, Zhang, Tian, George, Daniel J, Armstrong, Andrew J
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.04.2022
Témata:	Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - adverse effects Carcinoma, Neuroendocrine - pathology Cell activation Central nervous system Coronaviruses COVID-19 CXCR2 protein Histology Humans Immune system Immunotherapy Lymphocytes T Male Medical prognosis Metastases Middle Aged Monoclonal antibodies MSH2 protein Mutation Pandemics Patients PD-L1 protein Peripheral blood Phenotyping Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Remission Response rates Safety Survival Targeted cancer therapy Toxicity
ISSN:	1365-7852, 1476-5608, 1476-5608
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!